

Zeina Ghorab

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1474123/publications.pdf>

Version: 2024-02-01

13
papers

61
citations

1937685

4
h-index

1588992

8
g-index

13
all docs

13
docs citations

13
times ranked

92
citing authors

#	ARTICLE	IF	CITATIONS
1	^Serum-derived carcinoembryonic antigen (^{CEA}) activates fibroblasts to induce a local re-modeling of the extracellular matrix that favors the engraftment of ^{CEA}-expressing tumor cells. International Journal of Cancer, 2018, 143, 1963-1977.	5.1	18
2	Breast implant-associated EBV-positive diffuse large B-cell lymphoma: Two case reports and literature review. Pathology Research and Practice, 2021, 226, 153589.	2.3	12
3	Cytology-based screening for anal intraepithelial neoplasia in women with a history of cervical intraepithelial neoplasia or cancer. Cancer Cytopathology, 2021, 129, 140-147.	2.4	11
4	A Challenging Diagnosis of IgG4-Related Disease When Understanding Limitations of Laboratory Testing Was Pivotal. Case Reports in Medicine, 2017, 2017, 1-5.	0.7	4
5	Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with ⁹⁰Y ibritumomab tiuxetan in a phase II study. Hematological Oncology, 2018, 36, 525-532.	1.7	4
6	Autologous stem cell transplant and combination immunotherapy of rituximab and interferon- α induces prolonged clinical and molecular remissions in patients with follicular lymphoma. British Journal of Haematology, 2019, 184, 469-472.	2.5	4
7	Rituximab Increases Response to ESHAP in Relapsed, Refractory, and Transformed Aggressive B-Cell Lymphoma.. Blood, 2006, 108, 3067-3067.	1.4	4
8	Horner syndrome secondary to Hodgkin lymphoma. Cmaj, 2020, 192, E187-E187.	2.0	2
9	Pre-operative diagnosis of a Brunner's gland hamartoma by endoscopic ultrasound-guided fine needle aspiration. Cytopathology, 2021, 32, 674-676.	0.7	1
10	Comparison of ACR-TIRADS to the ATA Guidelines for Thyroid Nodules: A Neck to Neck Comparison. , 2022, 1, 1-8.		1
11	First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan (90Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma. Blood, 2011, 118, 2701-2701.	1.4	0
12	Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors >1, Treated Front Line with R-CHOP Followed by Consolidative 90 Y-Radioimmunotherapy and Maintenance Rituximab. Blood, 2012, 120, 3681-3681.	1.4	0
13	Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan. Blood, 2016, 128, 1794-1794.	1.4	0